Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : CYC065
CAS No.: 1070790-89-4
Catalog No.: PC-61248Not For Human Use, Lab Use Only.
CYC065 (Fadraciclib) is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $158 | In stock | |
| 10 mg | $228 | In stock | |
| 25 mg | $368 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
CYC065 (Fadraciclib) is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
CYC065 demonstrates cytotoxicity both in MM cell lines sensitive as well as resistant to conventional chemotherapy with IC50 of 0.06-2 uM.
CYC065 blocks cells in the G1 phase and inhibits cell growth specifically in CCNE1-overexpressing USCs.
CYC065 significantly reduces tumour growth in xenografts derived from CCNE1-amplified USCs.
CYC065 shows synergistic effect in vitro and in vivo combined with Taselisib.
| M.Wt | 397.527 | |
| Formula | C21H31N7O | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
DMSO: 100 mg/mL |
|
| Chemical Name/SMILES |
(2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol |
|
1. Cocco E, et al. Br J Cancer. 2016 Jul 26;115(3):303-11.
2. Kawakami M, et al. J Natl Cancer Inst. 2017 Jun 1;109(6).
3. Thomas AL, et al. Cell Cycle. 2017 Aug 3;16(15):1453-1464.
4. Rao SS, et al. Oncotarget. 2017 Aug 10;8(48):83925-83939.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
